Table 3.

Comparison of 233 patients with and without CRE acquisition during hospitalization.

Variables	CRE Colonization (N = 66)	No CRE Colonization (N = 167)	p Value
Antibiotic use during hospitalization
Beta-lactams/beta-lactamase inhibitors	39 (59.1%)	87 (52.1%)	0.33
Cephalosporins	31 (47.0%)	81 (48.5%)	0.84
Carbapenems	22 (33.3%)	47 (28.1%)	0.43
Fluoroquinolones	14 (21.2%)	33 (19.8%)	0.80
Vancomycin	13 (19.7%)	22 (13.2%)	0.21
Macrolide	10 (15.2%)	18 (10.8%)	0.36
Colistin	6 (9.1%)	9 (5.4%)	0.37
Penicillins	5 (7.6%)	11 (6.6%)	0.78
Aminoglycosides	3 (4.5%)	2 (1.2%)	0.14
Fosfomycin	1 (1.5%)	3 (1.8%)	1.00
Procedure during hospitalization
Indwelling urinary catheter	49 (74.2%)	117 (70.1%)	0.53
Mechanical ventilator	28 (42.4%)	60 (35.9%)	0.36
Central venous catheterization	20 (30.3%)	28 (16.8%)	0.02
Surgery	13 (19.7%)	17 (10.2%)	0.05
Principal diagnosis in this admission
Pulmonary diseases	18 (27.3%)	46 (27.5%)	0.97
Gastrointestinal/hepatic diseases	9 (13.6%)	28 (16.8%)	0.56
Heart diseases	9 (13.6%)	21 (12.6%)	0.83
Renal diseases	6 (9.1%)	18 (10.8%)	0.70
Cerebrovascular diseases	9 (13.6%)	16 (9.6%)	0.37
Solid malignancy	5 (7.6%)	12 (7.2%)	1.00
Autoimmune diseases	2 (3.0%)	9 (5.4%)	0.73
Hematological malignancy	2 (9.0%)	8 (4.8%)	0.73
Diagnosis of infection during hospitalization
Respiratory tract infection	37 (56.1%)	69 (41.3%)	0.04
Urinary tract infection	16 (24.2%)	25 (15.1%)	0.10
Gastrointestinal/hepatobiliary tract infection	15 (22.7%)	17 (10.2%)	0.01
Bloodstream infection	7 (10.6%)	22 (13.2%)	0.59
Skin and soft tissue infection	5 (7.6%)	23 (13.8%)	0.19
Central nervous system infection	2 (3.0%)	4 (2.4%)	0.68
Cardiovascular system infection	1 (1.5%)	0 (0.0%)	0.29
Median length of hospitalization (range), days	23.5 (3–177)	13 (2–71)	<0.001
All-cause mortality at hospital discharge	18 (27.3%)	33 (19.8%)	0.21